• Open Access

Taking Open Innovation to the Molecular Level - Strengths and Limitations

Authors

  • Barbara Zdrazil,

    Corresponding author
    1. University of Vienna, Department of Medicinal Chemistry, Pharmacoinformatics Research Group, Althanstrasse 14, 1090 Vienna, Austria phone/fax: +43-1-4277-55115/+43-1-4277-9551
    • University of Vienna, Department of Medicinal Chemistry, Pharmacoinformatics Research Group, Althanstrasse 14, 1090 Vienna, Austria phone/fax: +43-1-4277-55115/+43-1-4277-9551
    Search for more papers by this author
  • Niklas Blomberg,

    1. Medicinal Chemistry, Respiratory and Inflammation iMED, AstraZeneca R&D Mölndal, S-43183 Mölndal, Sweden
    Search for more papers by this author
  • Gerhard F. Ecker

    1. University of Vienna, Department of Medicinal Chemistry, Pharmacoinformatics Research Group, Althanstrasse 14, 1090 Vienna, Austria phone/fax: +43-1-4277-55115/+43-1-4277-9551
    Search for more papers by this author

Abstract

The ever-growing availability of large-scale open data and its maturation is having a significant impact on industrial drug-discovery, as well as on academic and non-profit research. As industry is changing to an ‘open innovation’ business concept, precompetitive initiatives and strong public-private partnerships including academic research cooperation partners are gaining more and more importance. Now, the bioinformatics and cheminformatics communities are seeking for web tools which allow the integration of this large volume of life science datasets available in the public domain. Such a data exploitation tool would ideally be able to answer complex biological questions by formulating only one search query. In this short review/perspective, we outline the use of semantic web approaches for data and knowledge integration. Further, we discuss strengths and current limitations of public available data retrieval tools and integrated platforms.

Ancillary